Spondyloarthritis & psoriatic arthritis
Osteoclast development from peripheral blood monocytes is reduced in patients with radiographic axial spondyloarthritis on biological therapy
Authors' conclusion
Our study demonstrates that patients with r-axSpA exhibit a reduced capacity for osteoclast formation from CD14 + monocytes isolated from peripheral blood.
Study context
- Population
- Patients with long-standing radiographic axial spondyloarthritis (r-axSpA) and blood-donor controls; CD14+ monocytes differentiated into osteoclasts in vitro (macrophage colony-stimulating factor (M-CSF); M-CSF + RANKL; M-CSF + RANKL + TNF)
- Comparison
- r-axSpA patients vs blood-donor controls
- r-axSpAn = 28
- Controlsn = 16reference
- Outcome
- Osteoclast development capacity from peripheral blood monocytes (tartrate-resistant acid phosphatase (TRAP) staining; TRAP5b in supernatants by ELISA)
Methodological detailsin vitro osteoclast differentiation
- In vitro osteoclast differentiation
Main finding
As reported in the abstract
- Frequency of CD14+ monocytes similar in r-axSpA and controls
- Capacity to develop osteoclasts and osteoclast precursors significantly decreased in r-axSpA vs controls
- Only r-axSpA patients on bDMARDs had reduced ability to develop osteoclasts and precursors vs those not on bDMARDs and controls
- Lower Trap5b concentrations in supernatants corroborated these findings
Further findings
Ankylosing Spondylitis Disease Activity Score (ASDAS) and CD14+ monocyte frequency, bDMARDs vs no bDMARDs
- No significant differences
Original publication
Osteoclast development from peripheral blood monocytes is reduced in patients with radiographic axial spondyloarthritis on biological therapy. Arthritis Res Ther. Published 30 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →